ConductScience.org, home

Paper34901302

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.

Rebold N and 15 others. Open Forum Infect Dis, 2021. Cited by 27 papers, by iCite.

Cite this record

ConductScience Library. Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Papers, record 34901302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34901302

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections.
PubMed
Journal
Open Forum Infect Dis
PubMed
Year
2021
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
2.33
iCite
Revised in PubMed
2026-05-26
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rebold NNicholashttps://orcid.org/0000-0002-5469-1228
2Morrisette TTaylorhttps://orcid.org/0000-0002-1094-043X
3Lagnf AMAbdalhamid M
4Alosaimy SSarahttps://orcid.org/0000-0001-8349-7531
5Holger DDana
6Barber KKatiehttps://orcid.org/0000-0002-8411-3111
7Justo JAJulie Annhttps://orcid.org/0000-0002-4161-9577
8Antosz KKayla
9Carlson TJTravis Jhttps://orcid.org/0000-0001-9564-3030
10Frens JJJeremy J
11Biagi MMarkhttps://orcid.org/0000-0001-5190-0066
12Kufel WDWesley Dhttps://orcid.org/0000-0001-7703-096X
13Moore WJWilliam J
14Mercuro NNicholashttps://orcid.org/0000-0001-7619-8736
15Raux BRBrian Rhttps://orcid.org/0000-0003-0183-216X
16Rybak MJMichael Jhttps://orcid.org/0000-0003-2220-0081

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
R01 AI121400NIAID NIH HHSUnited StatesR01AI121400PubMed

Source NIH RePORTER

Download CSV of grants

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
118929686Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform2009https://conductscience.org/library/papers/18929686PubMed
233191112
The safety and efficacy of relebactam/imipenem/cilastatin in Japanese patients with complicated intra-abdominal infection or complicated urinary tract infection: A multicenter, open-label, noncomparative phase 3 study.
J Infect Chemother2021https://conductscience.org/library/papers/33191112PubMed
327098166Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.Clin Infect Dis2016https://conductscience.org/library/papers/27098166PubMed
429230684Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Drugs2018https://conductscience.org/library/papers/29230684PubMed
531272373In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.BMC Microbiol2019https://conductscience.org/library/papers/31272373PubMed
621793988Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.Clin Microbiol Infect2012https://conductscience.org/library/papers/21793988PubMed
731400759
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections.
Clin Infect Dis2020https://conductscience.org/library/papers/31400759PubMed
828584849Carbapenem-Resistant Enterobacteriaceae Infections: Results From a Retrospective Series and Implications for the Design of Prospective Clinical Trials.Open Forum Infect Dis2017https://conductscience.org/library/papers/28584849PubMed
91244564Prediction of creatinine clearance from serum creatinine.Nephron1976https://conductscience.org/library/papers/1244564PubMed
1026289307The β-Lactams Strike Back: Ceftazidime-Avibactam.Pharmacotherapy2015https://conductscience.org/library/papers/26289307PubMed
1124957843Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24957843PubMed
1233830222
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
Clin Infect Dis2021https://conductscience.org/library/papers/33830222PubMed
1326014931Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/26014931PubMed
147249508A method for estimating the probability of adverse drug reactions.Clin Pharmacol Ther1981https://conductscience.org/library/papers/7249508PubMed
1527589330Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Virulence2017https://conductscience.org/library/papers/27589330PubMed
1623696619Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa.J Antimicrob Chemother2013https://conductscience.org/library/papers/23696619PubMed
1729610205Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29610205PubMed
1825070493New options of antibiotic combination therapy for multidrug-resistant Pseudomonas aeruginosa.Eur J Clin Microbiol Infect Dis2015https://conductscience.org/library/papers/25070493PubMed
193928249APACHE II: a severity of disease classification system.Crit Care Med1985https://conductscience.org/library/papers/3928249PubMed
2032785589
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Clin Infect Dis2021https://conductscience.org/library/papers/32785589PubMed

See all 22 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
42967154Responsible use of new antibiotics for critically ill patients suffering from infections due to carbapenem-resistant organisms-a narrative review for an enablement strategy.JAC Antimicrob Resist2026https://conductscience.org/library/papers/42967154PubMed
42016367Multicenter Evaluation of Ceftazidime/Avibactam in Pediatric Patients Across the United States: Real-World Insights into the Management of Drug-Resistant Gram-Negative Infections.Open Forum Infect Dis2026https://conductscience.org/library/papers/42016367PubMed
41867387Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports.J Blood Med2026https://conductscience.org/library/papers/41867387PubMed
41384153Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.Infez Med2025https://conductscience.org/library/papers/41384153PubMed
40583996Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC Antimicrob Resist2025https://conductscience.org/library/papers/40583996PubMed
40426594Breaking Through Resistance: A Comparative Review of New Beta-Lactamase Inhibitors (Avibactam, Vaborbactam, Relebactam) Against Multidrug-Resistant Superbugs.Antibiotics (Basel)2025https://conductscience.org/library/papers/40426594PubMed
39612160Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study).Infect Dis Ther2025https://conductscience.org/library/papers/39612160PubMed
39545060
First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion.
Front Pharmacol2024https://conductscience.org/library/papers/39545060PubMed
39081883
Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience.
Front Microbiol2024https://conductscience.org/library/papers/39081883PubMed
38792635Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence.Life (Basel)2024https://conductscience.org/library/papers/38792635PubMed
38174096Global Resistance of Imipenem/Relebactam against Gram-Negative Bacilli: Systematic Review and Meta-Analysis.Curr Ther Res Clin Exp2024https://conductscience.org/library/papers/38174096PubMed
37383243Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.Open Forum Infect Dis2023https://conductscience.org/library/papers/37383243PubMed
37107124Novel Antimicrobial Agents for Gram-Negative Pathogens.Antibiotics (Basel)2023https://conductscience.org/library/papers/37107124PubMed
36968951Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.JAC Antimicrob Resist2023https://conductscience.org/library/papers/36968951PubMed
36544909Last resort beta-lactam antibiotics for treatment of New-Delhi Metallo-Beta-Lactamase producing Enterobacterales and other Difficult-to-Treat Resistance in Gram-negative bacteria: A real-life study.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36544909PubMed
36140042Epidemiology, Mechanisms of Resistance and Treatment Algorithm for Infections Due to Carbapenem-Resistant Gram-Negative Bacteria: An Expert Panel Opinion.Antibiotics (Basel)2022https://conductscience.org/library/papers/36140042PubMed
35892399Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients.Antibiotics (Basel)2022https://conductscience.org/library/papers/35892399PubMed
35727059New Perspectives on Antimicrobial Agents: Imipenem-Relebactam.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/35727059PubMed
35625223New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review.Antibiotics (Basel)2022https://conductscience.org/library/papers/35625223PubMed
35203879The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations.Antibiotics (Basel)2022https://conductscience.org/library/papers/35203879PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
DPEP11800PubTator's text mininghttps://conductscience.org/library/genes/1800NCBI Gene
INSR3643PubTator's text mininghttps://conductscience.org/library/genes/3643NCBI Gene
OPRD14985PubTator's text mininghttps://conductscience.org/library/genes/4985NCBI Gene
UBAC110422PubTator's text mininghttps://conductscience.org/library/genes/10422NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/34901302

GET https://conductscience.org/api/papers/v1/34901302/references?page=2